within Pharmacolibrary.Drugs.N_NervousSystem.N06A_Antidepressants.N06AB10_Escitalopram;

model Escitalopram
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.8,
    Cl = 1.1666666666666666e-05,
    adminDuration = 600,
    adminMass = 20 / 1000000,
    adminCount = 1,
    Vd = 0.0126,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.008166666666666666,
    Tlag = 9.6,
    Vdp = 0.0075,
    k12 = 9.527777777777778e-06,
    k21 = 9.527777777777778e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Escitalopram</td></tr><tr><td>ATC code:</td><td>N06AB10</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>20</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>12.6</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.6</td><td>L/h/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Escitalopram is a selective serotonin reuptake inhibitor (SSRI) antidepressant used for the treatment of major depressive disorder, generalized anxiety disorder, social anxiety disorder, and panic disorder in adults. It is currently approved and widely used in clinical practice.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers, both male and female.</p><h4>References</h4><ol><li><p>Courlet, P, et al., &amp; Csajka, C (2019). Escitalopram population pharmacokinetics in people living with human immunodeficiency virus and in the psychiatric population: Drug-drug interactions and probability of target attainment. <i>British journal of clinical pharmacology</i> 85(9) 2022–2032. DOI:<a href=\"https://doi.org/10.1111/bcp.13994\">10.1111/bcp.13994</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31144347/\">https://pubmed.ncbi.nlm.nih.gov/31144347</a></p></li><li><p>Nilausen, DØ, et al., &amp; van Gerven, J (2011). The perception and pharmacokinetics of a 20-mg dose of escitalopram orodispersible tablets in a relative bioavailability study in healthy men. <i>Clinical therapeutics</i> 33(10) 1492–1502. DOI:<a href=\"https://doi.org/10.1016/j.clinthera.2011.09.012\">10.1016/j.clinthera.2011.09.012</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/21999886/\">https://pubmed.ncbi.nlm.nih.gov/21999886</a></p></li><li><p>Schmitt, L, et al., &amp; Tonnoir, B (2006). [Safety and efficacy of oral escitalopram as continuation treatment of intravenous citalopram, in patients with major depressive disorder--the navigade switch study]. <i>L&#x27;Encephale</i> 32(2 Pt 1) 270–277. DOI:<a href=\"https://doi.org/10.1016/s0013-7006(06)76154-1\">10.1016/s0013-7006(06)76154-1</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/16910629/\">https://pubmed.ncbi.nlm.nih.gov/16910629</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.N.N06AB10 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Escitalopram;
